Rallybio Corporation
NASDAQ:RLYB
0.32 (USD) • At close April 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.038 | 0.299 | 0.299 | 0 | 0.228 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0.034 | 0.035 | 0.036 | 0.037 | 0.038 | 0.039 | 0 | 0.042 | 0.044 | 0.042 | 0.035 | 0.026 | 0.025 | 0.023 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.038 | 0.299 | 0.265 | -0.035 | 0.192 | -0.037 | -0.038 | -0.039 | 0 | -0.042 | -0.044 | -0.042 | -0.035 | -0.026 | -0.025 | -0.023 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 1 | 0.886 | 0 | 0.842 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 7.385 | 8.24 | 12.912 | 12.901 | 15.888 | 13.288 | 13.13 | 11.202 | 10.793 | 12.11 | 10.138 | 7.648 | 6.094 | 4.96 | 6.818 | 9.037 | 7.495 | 5.13 | 3.092 | 1.913 |
| General & Administrative Expenses
| 4.261 | 4.125 | 4.388 | 6.851 | 5.188 | 6.075 | 6.953 | 7.172 | 6.298 | 6.75 | 7.477 | 6.67 | 6.219 | 5.021 | 3.712 | 3.787 | 2.592 | 1.58 | 1.57 | 1.931 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.261 | 4.125 | 4.388 | 6.851 | 5.188 | 6.075 | 6.953 | 7.172 | 6.298 | 6.75 | 7.477 | 6.67 | 6.219 | 5.021 | 3.712 | 3.787 | 2.592 | 1.58 | 1.57 | 1.931 |
| Other Expenses
| 0 | 0 | 0.143 | 0.167 | 0.035 | 0.092 | 0.062 | 0.073 | 0 | 0.098 | 0.1 | 0.113 | 0.109 | 0.105 | -0.142 | 0.024 | 0.068 | 0.052 | 0.069 | 0.052 |
| Operating Expenses
| 11.646 | 12.365 | 17.3 | 19.752 | 21.076 | 19.363 | 20.083 | 18.374 | 17.091 | 18.86 | 17.615 | 14.318 | 12.313 | 9.981 | 10.53 | 12.824 | 10.087 | 6.71 | 4.662 | 3.844 |
| Operating Income
| -11.608 | -12.066 | -17.035 | -19.787 | -21.112 | -19.363 | -20.083 | -18.374 | -17.091 | -18.86 | -17.615 | -14.318 | -12.313 | -9.981 | -10.53 | -12.824 | -10.087 | -6.71 | -4.662 | -3.844 |
| Operating Income Ratio
| -305.474 | -40.355 | -56.973 | 0 | -92.596 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.564 | 0.6 | 0.799 | 0.758 | 1.483 | 0.989 | 1.453 | 1.056 | 1.102 | 0.49 | 0.37 | 0.21 | 0.121 | 0.117 | -0.129 | 0.031 | -0.43 | 0.081 | 0.104 | 0.095 |
| Income Before Tax
| -11.044 | -11.466 | -15.749 | -18.344 | -19.629 | -18.374 | -18.413 | -16.755 | -15.989 | -18.237 | -17.245 | -14.108 | -12.192 | -9.864 | -10.659 | -12.793 | -10.004 | -6.629 | -4.558 | -3.749 |
| Income Before Tax Ratio
| -290.632 | -38.348 | -52.672 | 0 | -86.092 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0.487 | 0.685 | 0.613 | -0.037 | 0.217 | -1.095 | 0.214 | -0.434 | 0.068 | 0.293 | 0.102 | 0.437 | 0.468 | 0.516 | 0.001 | 0.591 | 0.416 | -0.016 |
| Net Income
| -11.044 | -11.466 | -16.236 | -19.029 | -20.242 | -18.374 | -18.63 | -15.66 | -16.203 | -17.803 | -17.583 | -14.401 | -12.415 | -10.196 | -11.127 | -13.275 | -10.518 | -7.155 | -4.893 | -3.881 |
| Net Income Ratio
| -290.632 | -38.348 | -54.301 | 0 | -88.781 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.25 | -0.26 | -0.37 | -0.47 | -0.5 | -0.45 | -0.46 | -0.39 | -0.46 | -0.58 | -0.57 | -0.47 | -0.42 | -0.37 | -0.36 | -0.6 | -0.47 | -0.32 | -0.22 | -0.17 |
| EPS Diluted
| -0.25 | -0.26 | -0.37 | -0.47 | -0.5 | -0.45 | -0.46 | -0.39 | -0.46 | -0.58 | -0.57 | -0.47 | -0.42 | -0.37 | -0.36 | -0.6 | -0.47 | -0.32 | -0.22 | -0.17 |
| EBITDA
| -11.578 | -12.034 | -17.001 | -19.752 | -21.076 | -19.326 | -20.045 | -18.335 | -15.95 | -18.195 | -17.571 | -14.066 | -12.157 | -9.838 | -10.634 | -12.76 | -9.972 | -6.601 | -4.532 | -3.724 |
| EBITDA Ratio
| -304.684 | -40.247 | -56.86 | 0 | -92.439 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |